MOTIF BIO PLC/S (NASDAQ:MTFB) shares were down 6.3% during trading on Friday . The company traded as low as $0.13 and last traded at $0.15, approximately 584,317 shares changed hands during trading. An increase of 59% from the average daily volume of 366,707 shares. The stock had previously closed at $0.16.
A number of research analysts have commented on MTFB shares. Zacks Investment Research upgraded shares of MOTIF BIO PLC/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. Northland Securities set a $5.00 price target on shares of MOTIF BIO PLC/S and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, ValuEngine upgraded shares of MOTIF BIO PLC/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
The business’s 50 day simple moving average is $0.29 and its 200 day simple moving average is $0.89. The stock has a market cap of $2.67 million, a P/E ratio of -2.14 and a beta of -0.12.
MOTIF BIO PLC/S Company Profile (NASDAQ:MTFB)
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Featured Story: What is operating income?
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.